


TITAX AMI

Prospective, Multi-center, Randomized Trial

TiTAN2™ vs. **T**AxUS Liberté™



18-MONTH FOLLOW-UP

TRIAL DESIGN

- 425 patients enrolled
- Randomization 1:1
- Endpoints: MACE at 6, 12 and 18 months

PATIENT INDICATIONS

	Ti TAN2 ™	T A xUS Liberté™	P value
NSTEMI	61%	54%	NS
STEMI	39%	46%	NS


CHARACTERISTICS

	Ti TAN2 ™	T A xUS Liberté™	P value
Diabetes, n (%)	22	16	0.08
B1/B2 lesions (%)	69	65	0.54
C lesions (%)	16	11	0.16
RVD (mm)	3.16 ± 0.45	3.11 ± 0.50	0.35
Lesion length (mm)	13.6 ± 5.6	13.2 ± 6.4	0.47

TITAX AMI


Prospective, Multi-center, Randomized Trial **TiTAN2™** vs. **TAXUS Liberté™**

18-MONTH RESULTS



TITAN2™
Efficacy and Safety significantly superior.

FOLLOW-UP AVAILABLE UP TO 18 MONTHS



TITAN2™ clinical efficacy sustained at 18 months.
10.3% of MACE at 12 and 18 months

HEXACATH

4, Passage Saint-Antoine
92508 Rueil-Malmaison Cedex
Tel: +33 (0)1 41 39 01 92
Fax: +33 (0)1 41 39 01 93
Web: www.hexacath.com

TCT 2008

TRANSCATHETER CARDIOVASCULAR THERAPEUTICS

Speaker: P. Karjalainen